24 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
10 Jun 24
Other Events
6:05am
mg: Dosed daily for 13 days
MAD Trial Patient Demographics Parameter Statistic All placebo (n=7) 25 mg CTI-1601 (n=6) 50 mg CTI-1601 (n=7) 100 mg CTI … / Disease Characteristics Data
Demographics – Phase 2 Trial 25 mg Cohort 50 mg Cohort Placebo N = 4 Nomlabofusp N = 9 Overall N = 13 Placebo N = 5
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
for 13 days
MAD Trial Patient Demographics Parameter Statistic All placebo (n=7) 25 mg CTI-1601 (n=6) 50 mg CTI-1601 (n=7) 100 mg CTI-1601 (n=7) All CTI … Characteristics Data
Demographics – Phase 2 Trial 25 mg Cohort 50 mg Cohort Placebo N = 4 Nomlabofusp N = 9 Overall N = 13 Placebo N = 5 Nomlabofusp N = 10
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
for 7 days, every other day thereafter 100 mg: Dosed daily for 13 days
MAD Trial Patient Demographics Parameter Statistic All placebo (n=7) 25 mg CTI … regimens for CTI-1601
Phase 2 Demographic/ Disease Characteristics Data
Demographics – Phase 2 Trial 25 mg Cohort 50 mg Cohort Placebo N = 4 Nomlabofusp
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
11 Mar 24
Other Events
4:09pm
Demographics Parameter Statistic All placebo (n=7) 25 mg CTI-1601 (n=6) 50 mg CTI-1601 (n=7) 100 mg CTI-1601 (n=7) All CTI-1601 (n=20) Overall (n=27) Sex Male n … evaluating once-daily and every-other-day dosing regimens for CTI-1601
Phase 2 Demographic/ Disease Characteristics Data
Demographics – Phase 2
8-K
EX-99.3
LRMR
Larimar Therapeutics Inc
12 Feb 24
Results of Operations and Financial Condition
7:03am
)
Demographics – Phase 2 Trial 25 mg Cohort 50 mg Cohort Placebo N = 4 Nomlabofusp N = 9 Overall N = 13 Placebo N = 5 Nomlabofusp N = 10 Overall N = 15 Age
8-K
EX-99.2
4k1qh2o
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
9erlq4w
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
ypcosoee3k4a55mn
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
e7a0s2f1kr
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
EX-99.2
2ffsy5xsn
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
EX-99.2
qeyiyb9ge9j7c
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
iqkabnaxe m9t
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
EX-99.2
0u8c upl4
14 Sep 22
Other Events
7:05am
8-K
EX-99.2
m0inl iqal7rm
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
EX-99.2
lu63qtt8b dm
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.2
4wix2g3hm 0x3
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
8-K
EX-99.1
0pnrleh7
28 Feb 22
Results of Operations and Financial Condition
8:16am
8-K
EX-99.2
hebif rwq
12 Nov 21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
7:21am
8-K
EX-99.2
vqnt0hig ag9rxa16ua9
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
EX-99.1
v9bb6 3wj
1 Jul 21
Other Events
6:11am